Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Eisai Receives Australian Approval for Halaven
September 10, 2012
- DSP Revising Midterm Business Plan – Will It Be Able to Hammer Out Effective Measures against Stagnant Domestic Business?
September 10, 2012
- Fuji-Keizai Predicts Antidepressant Market to Exceed 170 Billion Yen in 2020
September 7, 2012
- Kissei Aims for 40% Market Share for Epoetin Alfa at Early Stage
September 7, 2012
- Kyorin to Appoint Yoshida of MSD as Kyorin Pharmaceutical Facilities President
September 7, 2012
- Sunovion Completes Acquisition of Elevation: DSP
September 7, 2012
- Revestive Receives European Market Authorization for Short Bowel Syndrome: Takeda
September 6, 2012
- Nippon Shinyaku Plans Generic Launch to Complement Its New Drug Lineup in Priority Field
September 6, 2012
- AZ Aims to Become Market Leader with Symbicort on Additional Indication for COPD
September 6, 2012
- DSP Submits Imported Drug Registration Application in China for Anticancer Agent Calsed
September 6, 2012
- Meiji Seika Pharma Aims to Bolster Presence with COPD Drug Oxis
September 5, 2012
- Flu Vaccine Deal with BIKEN Hoped to Yield Synergies in Elderly Products: MSD Pres. Alvarez
September 5, 2012
- Anticancer Agent Enzalutamide Approved in the US: Astellas
September 5, 2012
- Halaven Approved in South Korea, To Be Launched in Jan. 2013: Eisai
September 5, 2012
- RaQualia to Focus on Fields Where It Can Exhibit Uniqueness, Compile Biz Strategy in November
September 4, 2012
- “Advancements in Domestic Business is Growth Driver” for Achieving Midterm Business Plan : MTPC President Tsuchiya
September 4, 2012
- Ono Ties Up with BioFocus of the UK for Drug Discovery for CNS Disorders
September 4, 2012
- Meiji Seika Pharma Launches COPD Treatment Oxis, Detailed by More Than 600 MRs
September 4, 2012
- Otsuka Applies for Abilify as Adjunctive Therapy for Depression; First Indication for Antipsychotic Drug in Japan
September 4, 2012
- MTPC to Double Number of Vaccine-Specialized MRs to 50, Eyeing TETRABIK Launch
September 3, 2012
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…